Eloxx Q2 net loss widens to $4.5 million; cash rises to $62.0 million after offering
Eloxx Pharmaceuticals reported a second-quarter 2026 net loss of $4.5 million, up from $1.9 million a year earlier, as research and development and general and administrative costs rose. The company completed a $66.0 million underwritten public offering in June 2026 and moved its listing to the Nasdaq Capital Market, and it says its cash will fund operations into mid-2028, which strengthens the balance sheet but adds new shares outstanding for existing holders.
Key points
- Net loss for the quarter ended June 30, 2026 was $4.5 million, compared with $1.9 million for the same quarter of 2025.
- The June 2026 underwritten offering had gross proceeds of $66.0 million and net proceeds of about $58.3 million.
- Cash and cash equivalents were $62.0 million at June 30, 2026, which the company expects to fund operations into mid-2028.
The filing
Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.